Clinical Trial Update: Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the safety and immunogenicity of a Melan-A virus-like particle (VLP) vaccine in patients with early-stage malignant melanoma reports …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Melan-A VLP vaccine (Melan-A virus-like particle vaccine)

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: COMPLETED